Skip to main content
Journal cover image

Circulating tumor cell-derived organoids: Current challenges and promises in medical research and precision medicine.

Publication ,  Journal Article
Praharaj, PP; Bhutia, SK; Nagrath, S; Bitting, RL; Deep, G
Published in: Biochim Biophys Acta Rev Cancer
April 2018

Traditional 2D cell cultures do not accurately recapitulate tumor heterogeneity, and insufficient human cell lines are available. Patient-derived xenograft (PDX) models more closely mimic clinical tumor heterogeneity, but are not useful for high-throughput drug screening. Recently, patient-derived organoid cultures have emerged as a novel technique to fill this critical need. Organoids maintain tumor tissue heterogeneity and drug-resistance responses, and thus are useful for high-throughput drug screening. Among various biological tissues used to produce organoid cultures, circulating tumor cells (CTCs) are promising, due to relative ease of ascertainment. CTC-derived organoids could help to acquire relevant genetic and epigenetic information about tumors in real time, and screen and test promising drugs. This could reduce the need for tissue biopsies, which are painful and may be difficult depending on the tumor location. In this review, we have focused on advances in CTC isolation and organoid culture methods, and their potential applications in disease modeling and precision medicine.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Biochim Biophys Acta Rev Cancer

DOI

ISSN

0304-419X

Publication Date

April 2018

Volume

1869

Issue

2

Start / End Page

117 / 127

Location

Netherlands

Related Subject Headings

  • Predictive Value of Tests
  • Precision Medicine
  • Organoids
  • Oncology & Carcinogenesis
  • Neoplastic Cells, Circulating
  • Neoplasms
  • Humans
  • High-Throughput Screening Assays
  • Drug Screening Assays, Antitumor
  • Drug Resistance, Neoplasm
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Praharaj, P. P., Bhutia, S. K., Nagrath, S., Bitting, R. L., & Deep, G. (2018). Circulating tumor cell-derived organoids: Current challenges and promises in medical research and precision medicine. Biochim Biophys Acta Rev Cancer, 1869(2), 117–127. https://doi.org/10.1016/j.bbcan.2017.12.005
Praharaj, Prakash P., Sujit K. Bhutia, Sunitha Nagrath, Rhonda L. Bitting, and Gagan Deep. “Circulating tumor cell-derived organoids: Current challenges and promises in medical research and precision medicine.Biochim Biophys Acta Rev Cancer 1869, no. 2 (April 2018): 117–27. https://doi.org/10.1016/j.bbcan.2017.12.005.
Praharaj PP, Bhutia SK, Nagrath S, Bitting RL, Deep G. Circulating tumor cell-derived organoids: Current challenges and promises in medical research and precision medicine. Biochim Biophys Acta Rev Cancer. 2018 Apr;1869(2):117–27.
Praharaj, Prakash P., et al. “Circulating tumor cell-derived organoids: Current challenges and promises in medical research and precision medicine.Biochim Biophys Acta Rev Cancer, vol. 1869, no. 2, Apr. 2018, pp. 117–27. Pubmed, doi:10.1016/j.bbcan.2017.12.005.
Praharaj PP, Bhutia SK, Nagrath S, Bitting RL, Deep G. Circulating tumor cell-derived organoids: Current challenges and promises in medical research and precision medicine. Biochim Biophys Acta Rev Cancer. 2018 Apr;1869(2):117–127.
Journal cover image

Published In

Biochim Biophys Acta Rev Cancer

DOI

ISSN

0304-419X

Publication Date

April 2018

Volume

1869

Issue

2

Start / End Page

117 / 127

Location

Netherlands

Related Subject Headings

  • Predictive Value of Tests
  • Precision Medicine
  • Organoids
  • Oncology & Carcinogenesis
  • Neoplastic Cells, Circulating
  • Neoplasms
  • Humans
  • High-Throughput Screening Assays
  • Drug Screening Assays, Antitumor
  • Drug Resistance, Neoplasm